-
Insights from Dr. Charles Flexner on Replacing Oral HIV Medications with Long-acting Drugs
In recent years, there have been many groundbreaking developments in the prevention and treatment of HIV infections with long-acting formulations. The LATITUDE study on cabotegravir/rilpivirine for patients with poor adherence was reported in the clinical LBA at the CROI conference. Additionally, the conference featured several special sessions discussing how to optimize the use of long-acting…
-
Insights from Dr. Khalil Ghanem on the Challenges and Future of Syphilis Diagnosis, Treatment, and Prevention
As the incidence of syphilis continues to rise, clinicians are faced with an increasing number of patients with complex clinical presentations, posing significant challenges in patient management. At the 31st Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Khalil Ghanem from the Johns Hopkins University School of Medicine delivered a keynote on the diagnosis and…
-
Dr. Afam A. Okoye: Highlights and Prospects of HIV Curative Therapy Research
Antiretroviral therapy (ART) has significantly extended the lifespan and improved the quality of life for HIV-infected individuals, yet achieving a complete cure for HIV remains an unresolved challenge. HIV’s characteristic of latent infection allows it to persist in the body, hidden from the immune system, and reactivate upon cessation of ART. Thus, developing a curative…
-
The First Weekly Oral Treatment Plan! Dr. Amy Colson Shares Phase 2 Study Results of Islatravir Combined with Lenacapavir at the CROI Conference
Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently under development, while lenacapavir belongs to a new class of capsid inhibitors, both featuring long half-lives and highlighted as part of long-acting treatment strategies. Previously, the clinical development of islatravir was temporarily halted due to adverse events involving reductions in CD4 cells and lymphocytes. However,…
-
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy
In the challenging field of hematology, the search for effective treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after CAR-T therapy failure is crucial. Professor Professor Haiwen Huang from The First Affiliated Hospital of Soochow University leads an innovative study exploring allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a promising alternative. This…
-
Dr.Taisheng Li’s Team Presents the “Chinese Solution” for HIV Immune Reconstitution Deficiency at CROI 2024
At the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held from March 3 to 6 in Denver, Colorado, USA, a study by Dr. Taisheng Li’s team from the Peking Union Medical College Hospital was selected for a poster presentation and discussed at the fifth session. This conference, which started in 1993, has become…
-
Dr. Shuihua Lu: First RCT Study Reported on a Novel Vaccine for Preventing Tuberculosis Relapse丨CROI Commentary
Patients who have successfully completed tuberculosis treatment still face a high risk of relapse, making the development of vaccines to prevent recurrent pulmonary tuberculosis an important direction in TB prevention efforts. At the recently concluded 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), a study presented as a late-breaking abstract (Abstract Number: 210) revealed…
-
Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary
In recent years, the concept of PAN-TB treatment, representing a comprehensive approach to tuberculosis (TB) therapy, has seen numerous developmental breakthroughs. This universal treatment method is applicable to all types of TB patients and is not limited by the resistance of traditional anti-tuberculosis drugs (i.e., there’s no need to test for drug resistance), offering advantages…
Connecting Medical Expertise through Media